Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MILFORD, Mass., May 06, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,...
-
MILFORD, Mass., May 06, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,...
-
MILFORD, Mass., April 21, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,...
-
SB 9200 followed by entecavir resulted in significant declines in viral DNA, RNA and surface antigens in the woodchuck model of HBV; results support advancement of SB 9200 to Phase 2 in HBV SB 9200...
-
MILFORD, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics using its proprietary chemistry...
-
MILFORD, Mass., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics using its proprietary small molecule...